{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:29:33Z","timestamp":1790357373203,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T00:00:00Z","timestamp":1604102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/igo"},{"start":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T00:00:00Z","timestamp":1604102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/igo"}],"funder":[{"DOI":"10.13039\/501100004099","name":"Ligue Contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Although anti-inflammatory agents could theoretically have anticancer properties, results from cohort studies on nonsteroidal anti-inflammatory drugs (NSAIDs) and breast cancer (BC) risk are inconsistent.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We investigated the association between NSAID use and BC incidence in the French E3N prospective cohort, which includes 98,995 women born between 1925 and 1950 and insured by a health insurance plan that covers mostly teachers. Self-reported information on lifestyle and medical history has been collected biennially by questionnaires and matched with data from a drug reimbursement database covering the period 2004\u20132014. Women who self-reported current NSAID use in the 2000 or 2002 questionnaires or with at least two reimbursements in any previous 3-month period were defined as exposed to NSAIDs. Multivariable Cox regression models were used to estimate hazard ratios (HRs) for the association of NSAID use with BC risk.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the current analysis, 62,512 postmenopausal women were followed between 2004 and 2014 (9\u2009years on average, starting at a mean age of 63\u2009years; 2864 incident BC). In multivariable models, there was no statistically significant association between NSAID use and BC risk [HR\u2009=\u20091.00 (0.92\u20131.08), compared with non-exposed women]. The NSAID-BC associations did not differ by NSAID types, BC subtypes, risk factors, and comorbidities, nor by duration and dose of use. However, a statistically significant interaction was observed by proton pump inhibitor (PPI) drug use (<jats:italic>P<\/jats:italic><jats:sub>interaction<\/jats:sub>\u2009=\u20090.01) whereby a decreased risk of BC with NSAID use was only observed among women who also used PPI before.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Only women who used NSAIDs after having used PPI had a lower risk of BC. This result is novel and requires replication in other studies.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13058-020-01343-1","type":"journal-article","created":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T13:03:13Z","timestamp":1604149393000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Use of nonsteroidal anti-inflammatory drugs and breast cancer risk in a prospective cohort of postmenopausal women"],"prefix":"10.1186","volume":"22","author":[{"given":"Manon","family":"Cairat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Al Rahmoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc J.","family":"Gunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Severi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Dossus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8380-3439","authenticated-orcid":false,"given":"Agn\u00e8s","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,31]]},"reference":[{"key":"1343_CR1","doi-asserted-by":"crossref","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u201342.","DOI":"10.3322\/caac.21492"},{"issue":"7","key":"1343_CR2","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1093\/carcin\/bgp127","volume":"30","author":"F Colotta","year":"2009","unstructured":"Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30(7):1073\u201381.","journal-title":"Carcinogenesis"},{"issue":"4","key":"1343_CR3","first-page":"559","volume":"13","author":"RE Harris","year":"2005","unstructured":"Harris RE, Beebe-Donk J, Doss H, Burr DD. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep. 2005;13(4):559\u201383.","journal-title":"Oncol Rep"},{"issue":"5","key":"1343_CR4","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/ar116","volume":"2","author":"J Steinmeyer","year":"2000","unstructured":"Steinmeyer J. Pharmacological basis for the therapy of pain and inflammation with nonsteroidal anti-inflammatory drugs. Arthritis Res. 2000;2(5):379\u201385.","journal-title":"Arthritis Res"},{"issue":"5","key":"1343_CR5","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/CEJ.0000000000000098","volume":"24","author":"E Yiannakopoulou","year":"2015","unstructured":"Yiannakopoulou E. Aspirin and NSAIDs for breast cancer chemoprevention. Eur J Cancer Prev. 2015;24(5):416\u201321.","journal-title":"Eur J Cancer Prev"},{"issue":"2","key":"1343_CR6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s10555-017-9675-z","volume":"36","author":"A Ornelas","year":"2017","unstructured":"Ornelas A, Zacharias-Millward N, Menter DG, Davis JS, Lichtenberger L, Hawke D, et al. Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention. Cancer Metastasis Rev. 2017;36(2):289\u2013303.","journal-title":"Cancer Metastasis Rev"},{"issue":"2","key":"1343_CR7","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s10549-015-3267-9","volume":"149","author":"M de Pedro","year":"2015","unstructured":"de Pedro M, Baeza S, Escudero MT, Dierssen-Sotos T, Gomez-Acebo I, Pollan M, et al. Effect of COX-2 inhibitors and other non-steroidal inflammatory drugs on breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2015;149(2):525\u201336.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1343_CR8","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1054\/bjoc.2000.1119","volume":"83","author":"CR Sharpe","year":"2000","unstructured":"Sharpe CR, Collet JP, McNutt M, Belzile E, Boivin JF, Hanley JA. Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer. 2000;83(1):112\u201320.","journal-title":"Br J Cancer"},{"issue":"11","key":"1343_CR9","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1038\/sj.bjc.6600945","volume":"88","author":"HT Sorensen","year":"2003","unstructured":"Sorensen HT, Friis S, Norgard B, Mellemkjaer L, Blot WJ, McLaughlin JK, et al. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer. 2003;88(11):1687\u201392.","journal-title":"Br J Cancer"},{"issue":"2","key":"1343_CR10","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/CEJ.0b013e3282b6fd55","volume":"17","author":"S Friis","year":"2008","unstructured":"Friis S, Thomassen L, Sorensen HT, Tjonneland A, Overvad K, Cronin-Fenton DP, et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort study. Eur J Cancer Prev. 2008;17(2):88\u201396.","journal-title":"Eur J Cancer Prev"},{"key":"1343_CR11","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/1471-2407-5-159","volume":"5","author":"E Rahme","year":"2005","unstructured":"Rahme E, Ghosn J, Dasgupta K, Rajan R, Hudson M. Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer. 2005;5:159.","journal-title":"BMC Cancer"},{"issue":"3","key":"1343_CR12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1592\/phco.22.5.303.33189","volume":"22","author":"CR Meier","year":"2002","unstructured":"Meier CR, Schmitz S, Jick H. Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy. 2002;22(3):303\u20139.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"1343_CR13","doi-asserted-by":"publisher","first-page":"R15","DOI":"10.1186\/bcr2482","volume":"12","author":"DP Cronin-Fenton","year":"2010","unstructured":"Cronin-Fenton DP, Pedersen L, Lash TL, Friis S, Baron JA, S\u00f8rensen HT. Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case-control study. Breast Cancer Res. 2010;12(2):R15.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"1343_CR14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.breast.2010.07.004","volume":"20","author":"V Ashok","year":"2011","unstructured":"Ashok V, Dash C, Rohan TE, Sprafka JM, Terry PD. Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk. Breast (Edinburgh, Scotland). 2011;20(1):66\u201370.","journal-title":"Breast (Edinburgh, Scotland)"},{"issue":"3","key":"1343_CR15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bjc.2011.252","volume":"105","author":"Y Vinogradova","year":"2011","unstructured":"Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to cyclooxygenase-2 inhibitors and risk of cancer: nested case-control studies. Br J Cancer. 2011;105(3):452\u20139.","journal-title":"Br J Cancer"},{"issue":"5","key":"1343_CR16","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/CEJ.0000000000000476","volume":"28","author":"CH Hung","year":"2019","unstructured":"Hung CH, Lin YC, Chang YH, Lin YC, Huang HY, Yeh WJ, et al. The effect of NSAIDs exposure on breast cancer risk in female patients with autoimmune diseases. Eur J Cancer Prev. 2019;28(5):428\u201334.","journal-title":"Eur J Cancer Prev"},{"issue":"3","key":"1343_CR17","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/sj.bjc.6602003","volume":"91","author":"LA Garcia Rodriguez","year":"2004","unstructured":"Garcia Rodriguez LA, Gonzalez-Perez A. Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. Br J Cancer. 2004;91(3):525\u20139.","journal-title":"Br J Cancer"},{"issue":"3","key":"1343_CR18","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00228-019-02810-1","volume":"76","author":"M Lassalle","year":"2020","unstructured":"Lassalle M, Le Tri T, Bardou M, Biour M, Kirchgesner J, Rouby F, et al. Use of proton pump inhibitors in adults in France: a nationwide drug utilization study. Eur J Clin Pharmacol. 2020;76(3):449\u201357.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"1343_CR19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2515\/therapie:2006029","volume":"61","author":"S Lugardon","year":"2006","unstructured":"Lugardon S, Roussel H, Bourrel R, Sciortino V, Montastruc JL, Lapeyre-Mestre M. Patterns of non steroidal anti-inflammatory drug use in ambulatory care. Therapie. 2006;61(2):109\u201314.","journal-title":"Therapie"},{"issue":"3","key":"1343_CR20","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1093\/ije\/dyu184","volume":"44","author":"F Clavel-Chapelon","year":"2015","unstructured":"Clavel-Chapelon F. Cohort profile: the French E3N cohort study. Int J Epidemiol. 2015;44(3):801\u20139.","journal-title":"Int J Epidemiol"},{"issue":"6","key":"1343_CR21","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1056\/NEJM200108093450607","volume":"345","author":"GA FitzGerald","year":"2001","unstructured":"FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345(6):433\u201342.","journal-title":"N Engl J Med"},{"key":"1343_CR22","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology: DDD: definition and general considerations. [Available from: http:\/\/www.whocc.no\/ddd\/definition_and_general_considera\/ ]."},{"issue":"8","key":"1343_CR23","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1200\/JCO.2007.13.4338","volume":"26","author":"A Fournier","year":"2008","unstructured":"Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol. 2008;26(8):1260\u20138.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1343_CR24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/pds.4145","volume":"26","author":"A Pottegard","year":"2017","unstructured":"Pottegard A, Hallas J. New use of prescription drugs prior to a cancer diagnosis. Pharmacoepidemiol Drug Saf. 2017;26(2):223\u20137.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"1343_CR25","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1002\/sim.2655","volume":"26","author":"M Pintilie","year":"2007","unstructured":"Pintilie M. Analysing and interpreting competing risk data. Stat Med. 2007;26(6):1360\u20137.","journal-title":"Stat Med"},{"issue":"2","key":"1343_CR26","doi-asserted-by":"publisher","first-page":"524","DOI":"10.2307\/2532940","volume":"51","author":"M Lunn","year":"1995","unstructured":"Lunn M, McNeil D. Applying Cox regression to competing risks. Biometrics. 1995;51(2):524\u201332.","journal-title":"Biometrics"},{"issue":"1","key":"1343_CR27","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13058-017-0840-7","volume":"19","author":"CA Clarke","year":"2017","unstructured":"Clarke CA, Canchola AJ, Moy LM, Neuhausen SL, Chung NT, Lacey JV Jr, et al. Regular and low-dose aspirin, other non-steroidal anti-inflammatory medications and prospective risk of HER2-defined breast cancer: the California Teachers Study. Breast Cancer Res. 2017;19(1):52.","journal-title":"Breast Cancer Res"},{"issue":"11","key":"1343_CR28","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1093\/jnci\/dji140","volume":"97","author":"SF Marshall","year":"2005","unstructured":"Marshall SF, Bernstein L, Anton-Culver H, Deapen D, Horn-Ross PL, Mohrenweiser H, et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst. 2005;97(11):805\u201312.","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"1343_CR29","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1093\/aje\/kwm195","volume":"166","author":"JK Gill","year":"2007","unstructured":"Gill JK, Maskarinec G, Wilkens LR, Pike MC, Henderson BE, Kolonel LN. Nonsteroidal antiinflammatory drugs and breast cancer risk: the multiethnic cohort. Am J Epidemiol. 2007;166(10):1150\u20138.","journal-title":"Am J Epidemiol"},{"key":"1343_CR30","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1186\/s12885-015-1979-1","volume":"15","author":"S Kim","year":"2015","unstructured":"Kim S, Shore DL, Wilson LE, Sanniez EI, Kim JH, Taylor JA, et al. Lifetime use of nonsteroidal anti-inflammatory drugs and breast cancer risk: results from a prospective study of women with a sister with breast cancer. BMC Cancer. 2015;15:960.","journal-title":"BMC Cancer"},{"issue":"1","key":"1343_CR31","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1158\/1055-9965.261.14.1","volume":"14","author":"EJ Jacobs","year":"2005","unstructured":"Jacobs EJ, Thun MJ, Connell CJ, Rodriguez C, Henley SJ, Feigelson HS, et al. Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev. 2005;14(1):261\u20134.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"18","key":"1343_CR32","first-page":"6096","volume":"63","author":"RE Harris","year":"2003","unstructured":"Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL, Anderson G, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women\u2019s Health Initiative. Cancer Res. 2003;63(18):6096\u2013101.","journal-title":"Cancer Res"},{"issue":"2","key":"1343_CR33","doi-asserted-by":"publisher","first-page":"R38","DOI":"10.1186\/bcr2089","volume":"10","author":"GL Gierach","year":"2008","unstructured":"Gierach GL, Lacey JV Jr, Schatzkin A, Leitzmann MF, Richesson D, Hollenbeck AR, et al. Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study. Breast Cancer Res. 2008;10(2):R38.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"1343_CR34","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.mayocp.2015.10.018","volume":"91","author":"A Bardia","year":"2016","unstructured":"Bardia A, Keenan TE, Ebbert JO, Lazovich D, Wang AH, Vierkant RA, et al. Personalizing aspirin use for targeted breast cancer chemoprevention in postmenopausal women. Mayo Clin Proc. 2016;91(1):71\u201380.","journal-title":"Mayo Clin Proc"},{"issue":"14","key":"1343_CR35","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1093\/jnci\/88.14.988","volume":"88","author":"KM Egan","year":"1996","unstructured":"Egan KM, Stampfer MJ, Giovannucci E, Rosner BA, Colditz GA. Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst. 1996;88(14):988\u201393.","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"1343_CR36","first-page":"1586","volume":"11","author":"TW Johnson","year":"2002","unstructured":"Johnson TW, Anderson KE, Lazovich D, Folsom AR. Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1586\u201391.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"1343_CR37","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1001\/archinternmed.2008.537","volume":"169","author":"AH Eliassen","year":"2009","unstructured":"Eliassen AH, Chen WY, Spiegelman D, Willett WC, Hunter DJ, Hankinson SE. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses\u2019 Health Study II. Arch Intern Med. 2009;169(2):115\u201321 discussion 21.","journal-title":"Arch Intern Med"},{"issue":"8","key":"1343_CR38","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1002\/ijc.28823","volume":"135","author":"TM Brasky","year":"2014","unstructured":"Brasky TM, Liu J, White E, Peters U, Potter JD, Walter RB, et al. Non-steroidal anti-inflammatory drugs and cancer risk in women: results from the Women\u2019s Health Initiative. Int J Cancer. 2014;135(8):1869\u201383.","journal-title":"Int J Cancer"},{"issue":"1","key":"1343_CR39","first-page":"71","volume":"6","author":"RE Harris","year":"1999","unstructured":"Harris RE, Kasbari S, Farrar WB. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep. 1999;6(1):71\u20133.","journal-title":"Oncol Rep"},{"issue":"11","key":"1343_CR40","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s10552-011-9832-6","volume":"22","author":"JL Bosco","year":"2011","unstructured":"Bosco JL, Palmer JR, Boggs DA, Hatch EE, Rosenberg L. Regular aspirin use and breast cancer risk in US Black women. Cancer Causes Control. 2011;22(11):1553\u201361.","journal-title":"Cancer Causes Control"},{"issue":"1","key":"1343_CR41","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/ijc.22656","volume":"121","author":"L Gallicchio","year":"2007","unstructured":"Gallicchio L, Visvanathan K, Burke A, Hoffman SC, Helzlsouer KJ. Nonsteroidal anti-inflammatory drugs and the risk of developing breast cancer in a population-based prospective cohort study in Washington County, MD. Int J Cancer. 2007;121(1):211\u20135.","journal-title":"Int J Cancer"},{"issue":"1","key":"1343_CR42","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s10549-010-1074-x","volume":"126","author":"A Bardia","year":"2011","unstructured":"Bardia A, Olson JE, Vachon CM, Lazovich D, Vierkant RA, Wang AH, et al. Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Res Treat. 2011;126(1):149\u201355.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"1343_CR43","doi-asserted-by":"publisher","first-page":"386","DOI":"10.23736\/S0026-4806.18.05705-1","volume":"109","author":"V Savarino","year":"2018","unstructured":"Savarino V, Marabotto E, Zentilin P, Furnari M, Bodini G, De Maria C, et al. The appropriate use of proton-pump inhibitors. Minerva Med. 2018;109(5):386\u201399.","journal-title":"Minerva Med"},{"issue":"7","key":"1343_CR44","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1111\/jgh.13737","volume":"32","author":"LH Eusebi","year":"2017","unstructured":"Eusebi LH, Rabitti S, Artesiani ML, Gelli D, Montagnani M, Zagari RM, et al. Proton pump inhibitors: risks of long-term use. J Gastroenterol Hepatol. 2017;32(7):1295\u2013302.","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"1343_CR45","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40264-014-0144-0","volume":"37","author":"R-S Wedemeyer","year":"2014","unstructured":"Wedemeyer R-S, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014;37(4):201\u201311.","journal-title":"Drug Saf"},{"issue":"1","key":"1343_CR46","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2174\/1871523011312010006","volume":"12","author":"B Lattuca","year":"2013","unstructured":"Lattuca B, Khoueiry Z, Malcles G, Davy JM, Leclercq F. Drug interactions between non-steroidal anti-inflammatory drugs and cardiovascular treatments (except anti-agregant therapy). Antiinflamm Antiallergy Agents Med Chem. 2013;12(1):36\u201346.","journal-title":"Antiinflamm Antiallergy Agents Med Chem"},{"issue":"11","key":"1343_CR47","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1007\/s10620-018-5122-4","volume":"63","author":"M Hojo","year":"2018","unstructured":"Hojo M, Asahara T, Nagahara A, Takeda T, Matsumoto K, Ueyama H, et al. Gut microbiota composition before and after use of proton pump inhibitors. Dig Dis Sci. 2018;63(11):2940\u20139.","journal-title":"Dig Dis Sci"},{"issue":"22","key":"1343_CR48","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.3748\/wjg.v25.i22.2706","volume":"25","author":"G Bruno","year":"2019","unstructured":"Bruno G, Zaccari P, Rocco G, Scalese G, Panetta C, Porowska B, et al. Proton pump inhibitors and dysbiosis: current knowledge and aspects to be clarified. World J Gastroenterol. 2019;25(22):2706\u201319.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"1343_CR49","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s00535-014-1032-1","volume":"50","author":"SD Syer","year":"2015","unstructured":"Syer SD, Blackler RW, Martin R, de Palma G, Rossi L, Verdu E, et al. NSAID enteropathy and bacteria: a complicated relationship. J Gastroenterol. 2015;50(4):387\u201393.","journal-title":"J Gastroenterol"},{"issue":"11","key":"1343_CR50","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/pds.1817","volume":"18","author":"C Damase-Michel","year":"2009","unstructured":"Damase-Michel C, Christaud J, Berrebi A, Lacroix I, Montastruc JL. What do pregnant women know about non-steroidal anti-inflammatory drugs? Pharmacoepidemiol Drug Saf. 2009;18(11):1034\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1343_CR51","unstructured":"Grandin M. Les anti-inflammatoires non st\u00e9ro\u00efdiens, utilisation et conseils dans la pratique officinale quotidienne. Document \u00e9tay\u00e9 par une analyse d\u2019ordonnances d\u2019une pharmacie rurale. In: Angers. Tpldd\u00e9ddepU, editor."},{"key":"1343_CR52","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.canep.2018.11.002","volume":"58","author":"T Tomi\u0107","year":"2019","unstructured":"Tomi\u0107 T, Dom\u00ednguez-L\u00f3pez S, Barrios-Rodr\u00edguez R. Non-aspirin non-steroidal anti-inflammatory drugs in prevention of colorectal cancer in people aged 40 or older: a systematic review and meta-analysis. Cancer Epidemiol. 2019;58:52\u201362.","journal-title":"Cancer Epidemiol"},{"key":"1343_CR53","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2147\/CLEP.S174120","volume":"10","author":"SK Veettil","year":"2018","unstructured":"Veettil SK, Jinatongthai P, Nathisuwan S, Teerawattanapong N, Ching SM, Lim KG, et al. Efficacy and safety of chemopreventive agents on colorectal cancer incidence and mortality: systematic review and network meta-analysis. Clin Epidemiol. 2018;10:1433\u201345.","journal-title":"Clin Epidemiol"},{"issue":"5","key":"1343_CR54","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2515\/therapie:2004092","volume":"59","author":"N Moore","year":"2004","unstructured":"Moore N, Diris H, Martin K, Viale R, Fourrier A, Moride Y, et al. NSAID use profiles derived from reimbursement data in France. Therapie. 2004;59(5):541\u20136.","journal-title":"Therapie"},{"issue":"11","key":"1343_CR55","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.yexcr.2013.04.018","volume":"319","author":"HA Martinson","year":"2013","unstructured":"Martinson HA, Lyons TR, Giles ED, Borges VF, Schedin P. Developmental windows of breast cancer risk provide opportunities for targeted chemoprevention. Exp Cell Res. 2013;319(11):1671\u20138.","journal-title":"Exp Cell Res"},{"issue":"7\u20139","key":"1343_CR56","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1387\/ijdb.113379jo","volume":"55","author":"J O'Brien","year":"2011","unstructured":"O'Brien J, Hansen K, Barkan D, Green J, Schedin P, O'Brien J, et al. Non-steroidal anti-inflammatory drugs target the pro-tumorigenic extracellular matrix of the postpartum mammary gland. Int J Dev Biol. 2011;55(7\u20139):745\u201355.","journal-title":"Int J Dev Biol"},{"key":"1343_CR57","unstructured":"Sivry P. Anti-Inflammatoires non st\u00e9ro\u00efdiens consomm\u00e9s en autom\u00e9dication : \u00e9valuation du niveau de connaissance de 334 patients de cabinets de m\u00e9decine g\u00e9n\u00e9rale des Alpes-Maritimes. M\u00e9decine humaine et pathologie. 2014. dumas-01219849."},{"key":"1343_CR58","unstructured":"Ghali M. Repr\u00e9sentation des patients \u00e0 propos des AINS oraux en vente libre. Th\u00e8se de Doctorat de M\u00e9decine. 2017."}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-020-01343-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13058-020-01343-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-020-01343-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T00:40:16Z","timestamp":1669423216000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-020-01343-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,31]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1343"],"URL":"https:\/\/doi.org\/10.1186\/s13058-020-01343-1","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,31]]},"assertion":[{"value":"11 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the French National Commission for Data Protection and Privacy, and all participants gave written informed consent for data collection and storage, as well as individual follow-up.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"118"}}